


# Laos BigBearPharma announces that all production facilities have received GMP licenses from the Lao FDD

*Laos GMP approval paves the way for BigBear pharma's next step in product marketing authorization.*

VIENTIANE, VIENTIANE, LAO PDR, March 3, 2023 /EINPresswire.com/ -- BigBear pharmaceutical.LTD (BigBear pharma) announced that it has obtained the Good Manufacturing Practices (GMP) certificate issued by the Lao Food and Drug Regulatory Authority.



The investor team of BigBear pharmaceutical went to Laos to investigate the investment environment in 2021, and formally invested in the construction of production facilities in 2022. After a year of engineering construction and improvement, it obtained the GMP certification issued by the Lao regulatory authority on January 16, 2023.

“

Thanks to the efforts of all staff, our manufacturing unit has obtained the pharmaceutical production license certification from the Lao regulatory authority as scheduled.”

*CEO Nipaporn Khunkaw*

This approval paves the way for the next step in product marketing authorization for BigBear pharma. The quality system adopted by the Lao food and drug regulatory authorities complies with EU GMP standards.

The CEO of BigBear pharma said: "Thanks to the hard work and efforts of all employees, as well as the support of investors, our manufacturing unit completed the construction and acceptance as scheduled, and at the same time obtained the pharmaceutical production license certification from the Lao regulatory authority. We are the latest generation of pharmaceutical companies in Laos , with a brand new production line and clean workshop. In view of this, I am very happy that we have good competitiveness in Southeast Asia."

About BigBear pharmaceutical. ([www.BigBearpharma.com](http://www.BigBearpharma.com))

BigBear pharmaceutical was established in 2022 with appropriate infrastructure including several separate production areas and associated packaging sections. As the latest generation of pharmaceutical companies in Laos, it has a modern preparation production workshop and is capable of manufacturing tablets, capsules, chronic disease drugs, anticancer drugs, herbal medicines and other main varieties. It can meet the common disease needs of patients in Asia, especially Southeast Asia.

Visit: [www.BigBearpharma.com](http://www.BigBearpharma.com) to know more information. As of the date of publication of this manuscript, the website is under construction and is expected to be completed and launched in mid-March.



BigBearPharma-GMP

### Forward-Looking Statements

To the extent applicable laws and regulations, expressions such as "plan," "target," "expect," "forecast," and similar expressions appearing in this press release are forward-looking statements. The forward-looking statements set forth herein involve a number of risks and uncertainties that may differ materially from actual results. Important factors leading to such differences include, but are not limited to, changes in regulations and/or economic conditions, uncertainty in clinical research results, exposure to various market risks, and other factors beyond the control of the company.

Spencer

RxLibra pharmaceutical Sole Co.,Ltd

20 54 177 436

info@rxlibra.com

This press release can be viewed online at: <https://www.einpresswire.com/article/620099387>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.